Arcus Biosciences (RCUS) announced results from Part 1 of ARC-10, a randomized, open-label, three-arm study evaluating domvanalimab, an ...

INBX's two main pipeline candidates are entering critical late-stage trials with data readouts expected in mid- to late-2025. Click here to read my analysis.

(RTTNews) - Arcus Biosciences, Inc. (RCUS), Tuesday announced results from part 1 of ARC-10, evaluating the effects of the combination of Domvanalimab and Zimberelimab versus Zimberelimab or ...

The following is a summary of "Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and ...

Despite the PDUFA date being extended by three months for Merus’ zenocutuzumab, Truist Securities analyst Asthika ...

The Protein Sequencing Companytm, today announced that it will be participating in two upcoming investment conferences. Jeff Hawkins, Quantum-Si's Chief Executive Officer, ...

Thanksgiving is a time to get together with family and friends for great food and lots of fun but it can easily turn into a nightmare if you have to spend the day in the emergency room. "Just eat ...

Q3 2024 Earnings Call Transcript November 4, 2024 Operator: Welcome to BioNTech’s Third Quarter 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor ...

Ophthalmic immune-related adverse events may point to a higher mortality risk in patients undergoing cancer treatment.

BioNTech said that its VEGF bispecific sets it apart from competitors because of its mechanism and how it plans to ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...